Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:


AURORA 1 reports efficacy of voclosporin in lupus nephritis

The AURORA 1 study reports that low-dose voclosporin added to standard immunosuppressive treatment improved rate of remission in patients with lupus nephritis. Further studies are needed to investigate the long-term efficacy and tolerability of voclosporin and to compare the effects of this treatment with those of low doses of tacrolimus or ciclosporin.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout


  1. Rovin, B. H. et al. Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 397, 2070–2080 (2021).

    Article  CAS  Google Scholar 

  2. Yap, D. Y. H., Tang, C. S. O., Ma, M. K. M., Lam, M. F. & Chan, T. M. Survival analysis and causes of mortality in patients with lupus nephritis. Nephrol. Dial. Transplant. 27, 3248–3254 (2012).

    Article  Google Scholar 

  3. Fanouriakis, A. et al. 2019 Update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann. Rheum. Dis. 79, 713–772 (2020).

    Article  CAS  Google Scholar 

  4. Naesens, M., Kuypers, D. R. & Sarwall, M. Calcineurin inhibitor nephrotoxicity. Clin. J. Am. Soc. Nephrol. 4, 481–508 (2009).

    Article  CAS  Google Scholar 

  5. Ling, S. Y. et al. Cytochrome P450 3A and P-glycoprotein drug-drug interactions with voclosporin. Br. J. Clin. Pharmacol. 77, 1039–1050 (2014).

    Article  CAS  Google Scholar 

  6. Birsan, T., Dambrin, C., Freitag, D. G., Yatscoff, R. W. & Morris, R. E. The novel calcineurin inhibitor ISA247: a more potent immunosuppressant than cyclosporine in vitro. Transpl. Int. 17, 767–771 (2005).

    Article  CAS  Google Scholar 

  7. Li, Y., Palmisano, M., Sun, D. & Zhou, S. Pharmacokinetic disposition difference between cyclosporine and voclosporin drives their distinct efficacy and safety profiles in clinical studies. Clin. Pharmacol. 12, 83–96 (2020).

    PubMed  PubMed Central  Google Scholar 

  8. Niaudet, P. & Habib, R. Cyclosporine in the treatment of idiopathic nephrosis. J. Am. Soc. Nephrol. 5, 1049–1056 (1994).

    Article  CAS  Google Scholar 

  9. Shiahb, F. S. Cyclosporine nephropathy: pathophysiology and clinical impact. Semin. Nephrol. 16, 536–547 (1996).

    Google Scholar 

  10. Faul, C. The actin cytoskeleton of podocytes is a direct target of antiproteinuric effect of cyclosporine. Nat. Med. 14, 931–938 (2008).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to Gabriella Moroni.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Moroni, G., Ponticelli, C. AURORA 1 reports efficacy of voclosporin in lupus nephritis. Nat Rev Nephrol 17, 637–638 (2021).

Download citation

  • Published:

  • Issue Date:

  • DOI:


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing